BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1532507)

  • 1. Goserelin (Zoladex) in the treatment of fibroids.
    West CP; Lumsden MA; Baird DT
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():27-30. PubMed ID: 1532507
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
    Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
    Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with LHRH analogue Zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata.
    Baird DT; Bramley TA; Hawkins TA; Lumsden MA; West CP
    Horm Res; 1989; 32 Suppl 1():154-6. PubMed ID: 2533146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
    McClelland HR; Quinn AJ
    Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
    Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
    Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy.
    Miller RM; Frank RA
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():37-41. PubMed ID: 1532509
    [No Abstract]   [Full Text] [Related]  

  • 9. Pretreatment with Zoladex improves surgery for uterine fibroids.
    Oncology (Williston Park); 1991 Jan; 5(1):94. PubMed ID: 1828691
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intrauterine pregnancy with uterine myoma after downregulation with GnRH analogs].
    Naether O; Diedrich K
    Geburtshilfe Frauenheilkd; 1992 Feb; 52(2):121-2. PubMed ID: 1314757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
    West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
    Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goserelin therapy before surgery for uterine fibroids.
    Lumsden MA; West CP; Baird DT
    Lancet; 1987 Jan; 1(8523):36-7. PubMed ID: 2879106
    [No Abstract]   [Full Text] [Related]  

  • 13. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
    Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630).
    Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT
    J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy.
    Maheux R; Lemay A
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():13-7. PubMed ID: 1532506
    [No Abstract]   [Full Text] [Related]  

  • 16. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.
    Gerris J; Degueldre M; Peters AA; Romao F; Stjernquist M; al-Taher H
    Horm Res; 1996; 45(6):279-84. PubMed ID: 8793522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
    Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R; Lemay A
    Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
    [No Abstract]   [Full Text] [Related]  

  • 20. [Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity].
    Nikolov A; Raĭcheva R; Maĭnkhard K
    Akush Ginekol (Sofiia); 1998; 37(1):55-7. PubMed ID: 9770805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.